Efinopegdutide

Merck is testing efinopegdutide (MK-6024), a once-weekly peptide hitting both GLP-1 and glucagon receptors, in MASH - the form of fatty liver disease where fat accumulation drives inflammation and scarring. A Phase 2a head-to-head against semaglutide cut liver fat by 72% versus 42% at 24 weeks, one of the largest liver fat differentials reported for any MASH agent in development [1]. The bet is that adding glucagon agonism to a GLP-1 backbone produces direct liver fat burning that semaglutide alone can't match - but Merck has to beat both Madrigal's already-approved resmetirom and semaglutide's incoming MASH label (FDA Priority Review accepted for Wegovy 2.4mg after ESSENCE Phase 3) to matter commercially [8][10]. The addressable population is large - roughly 14-16M U.S. adults have MASH, with 4-7M in the moderate-to-advanced fibrosis (F2-F3) segment where trials are run - but the field will likely have 3-4 approved agents by 2028-2029.

Investigational. Efinopegdutide is not approved anywhere. The molecule has a long history: developed by Korean biotech Hanmi as HM12525A, out-licensed to Janssen in 2015, returned in 2020, then picked up by Merck the same year. Currently in Phase 2 across the MASH/MASLD spectrum, with no Phase 3 announced. The lead study (NCT05877547) enrolled 381 patients with biopsy-confirmed precirrhotic NASH; recruitment is complete and biopsy readout is pending [2]. A second Phase 2 (NCT06465186) is testing the drug in compensated cirrhosis (F4 fibrosis), the harder, sicker population that resmetirom's key trial excluded; enrollment of 80 patients is closed, status is active not recruiting [3]. Two supporting Phase 1 studies have completed: hepatic impairment pharmacokinetics (NCT06052566) and a healthy obese cohort (NCT06701305), the latter signaling Merck is at least scoping the obesity indication. No FDA designations have been disclosed: no breakthrough therapy, no fast track, no orphan status. Merck has not provided public timeline guidance on Phase 3 initiation in 2025 or 2026 10-K filings [9]. Strategic context matters here: Keytruda - Merck's revenue anchor - loses U.S. exclusivity in 2028, so the company needs new mid-decade growth drivers, but efinopegdutide is not on the short list of Merck's named replacement assets. The next material event is the NCT05877547 biopsy readout, which will determine whether Merck commits the capital for a Phase 3 program in a MASH space that's already crowded and getting more so.

Efinopegdutide hits two hormone receptors at once: GLP-1 and glucagon. GLP-1 is the receptor behind Ozempic and Wegovy - when activated, it signals fullness in the brain, slows stomach emptying, and prompts the pancreas to release insulin when blood sugar rises. Glucagon is normally GLP-1's metabolic opposite: it tells the liver to release stored sugar (gluconeogenesis and glycogenolysis) and burn fat for energy. Combining both is a deliberate design choice. GLP-1 drives weight loss and improves insulin sensitivity, while glucagon activates fat oxidation specifically in the liver. Glucagon also signals the liver to release stored glucose - normally desirable for hepatic fat burning, but a real risk in the diabetic MASH population, where roughly 50-70% of patients carry type 2 diabetes and need glycemic control, not loosened glucose output. For fatty liver disease, where liver cells are packed with triglycerides that drive inflammation and eventually scarring, the dual signal is mechanistically attractive in a way pure GLP-1 isn't. The Phase 2a head-to-head against semaglutide 1mg (published in J Hepatol 2023) is the strongest validation: at 24 weeks, efinopegdutide 10mg cut liver fat by 72% versus 42% for semaglutide [1]. Important dose caveat: semaglutide 1mg is the diabetes dose, not the 2.4mg obesity dose Novo Nordisk used in ESSENCE and which will compete in the MASH market - meaning the head-to-head differential may compress against the higher dose. Weight loss in that Phase 2a was also greater in the efinopegdutide arm (8.5% versus 7.1% body weight at 24 weeks), so part of the liver fat advantage may be weight-mediated rather than purely a direct glucagon effect on hepatic lipid oxidation; the publication did not formally separate weight-adjusted from weight-independent contributions [1]. PEGylation (a polyethylene glycol chain attached to the peptide) extends the half-life enough to support once-weekly dosing. Recent meta-analyses of GLP-1-class drugs in MASLD/MASH confirm the class works on liver fat and on ALT, and dual agonists consistently outperform pure GLP-1 agents on imaging endpoints [6][7]. The mechanistic case is real but not airtight. The open question is whether better liver fat reduction translates to better NASH resolution and fibrosis improvement on biopsy, the endpoints regulators actually approve drugs on.

Two Phase 2 trials carry the program. NCT05877547 enrolled 381 patients with biopsy-confirmed NASH, fibrosis stages F1-F3 (precirrhotic). Primary endpoint: NASH resolution without worsening of fibrosis at week 52, on follow-up biopsy [2]. NASH resolution in this regulatory framework means histological disappearance of steatohepatitis - specifically, no more hepatocyte ballooning and a NAFLD activity score (NAS) of 0-1 for inflammation, with no increase in fibrosis stage. That's the same FDA-accepted surrogate Madrigal used for resmetirom's accelerated approval. Comparator is placebo. Enrollment is complete. This is the trial that decides whether efinopegdutide advances to Phase 3 in non-cirrhotic MASH. NCT06465186 is the riskier, smaller arm (n=80) in compensated cirrhosis (F4 fibrosis without decompensation). Primary endpoint is change in liver fat content at week 28 by MRI-PDFF (magnetic resonance imaging proton density fat fraction - a non-invasive imaging quantification of liver triglyceride content, expressed as a percentage of liver volume) - notably not biopsy, which tells you this is a de-risking and dosing study, not a registrational one [3]. Compensated cirrhosis is the wedge where Merck could carve clean differentiation versus resmetirom, which excluded F4 patients from MAESTRO-NASH. The supporting Phase 2 (NCT06482112, n=124) tested alternate dosing in MASLD, also reading liver fat by MRI-PDFF at week 28 [4]. Design quality is appropriate: biopsy endpoint in the lead study, imaging endpoints in the smaller arms, placebo controls throughout, and Merck running studies large enough to power them. The concern isn't design - it's that beyond the original Phase 2a, none of these studies include an active comparator, so Merck will have to win on absolute effect size versus historical placebo arms to convince payers and prescribers that efinopegdutide beats resmetirom and incoming semaglutide.

Our model gives this drug a 7% chance of eventual approval. That number starts from a historical baseline of about 23% for Phase 2 drugs in this area, then adjusts based on ten specific facts about the trial and sponsor. The estimate is helped by the sponsor's strong track record of getting drugs approved, but is pulled down by weak or limited earlier-phase results, a randomized design, and the presence of a comparator arm. The remaining factors fall close to average for this stage, so they leave the estimate roughly where the baseline put it.

Four buckets. Efficacy: liver fat reduction is well-established for GLP-1 class drugs, but biopsy-confirmed NASH resolution at 52 weeks is a harder endpoint that has killed many programs. The Phase 2a win was MRI-based and may have been partly mediated by greater weight loss in the efinopegdutide arm (8.5% vs 7.1%) [1]; the registrational-grade endpoint is histology, and translation isn't guaranteed. Safety: glucagon agonism is the open question. Glucagon raises hepatic glucose output, which can worsen glycemic control in diabetics - and a large fraction of the MASH population is diabetic. It also increases heart rate. Survodutide's Phase 2 showed real GI tolerability issues (nausea, vomiting) at effective doses, and efinopegdutide also showed slightly higher GI adverse event rates than semaglutide in the Phase 2a head-to-head [1]. The compensated cirrhosis arm carries the most acute safety risk: any signal of decompensation (ascites, encephalopathy, variceal bleed) in cirrhotic patients would end the program. Execution: trials are well-designed and Merck has the operational infrastructure to run them cleanly. Low risk here. Commercial: this is the real killer. Resmetirom (Rezdiffra) launched in March 2024 with oral once-daily dosing and is ramping fast as the first and only approved MASH drug [8]. Novo Nordisk's ESSENCE Phase 3 in MASH delivered 62.9% NASH resolution vs 34.3% placebo (semaglutide 2.4mg) and was published in NEJM in April 2025; FDA granted Priority Review for the MASH label [10]. Two FGF21 analogs are also closing in: Akero's efruxifermin and 89bio's pegozafermin, both in Phase 3 with strong fibrosis-improvement signals. Efinopegdutide as an injectable peptide entering a market where an oral drug, an established GLP-1, and two FGF21 analogs are ahead - with no clear differentiation other than the cirrhosis wedge - faces a brutal commercial setup unless the precirrhotic NASH biopsy data lands genuinely class-leading.

Worth watching, not a top-tier signal yet. The Phase 2a head-to-head against semaglutide is the one piece of data that makes this interesting - the liver fat differential was large enough that the dual-agonism mechanism appears to add value beyond GLP-1 alone, though some fraction of that may be weight-mediated (efinopegdutide arm lost 8.5% body weight vs 7.1% for semaglutide 1mg) [1]. MASH is the most crowded metabolic indication in clinical development right now, and the comparator was the diabetes-dose semaglutide; the head-to-head against the 2.4mg obesity dose hasn't been run. Merck has not signaled big strategic priority for efinopegdutide on recent earnings calls; it's a Phase 2 asset competing internally with the rest of Merck's diabetes and obesity portfolio, none of which is a top revenue driver against Keytruda - though Keytruda's 2028 LOE makes any credible mid-decade asset more interesting on the margin. The signal to watch is the NCT05877547 biopsy readout: NASH resolution rate is the number that matters [2]. Anything above 30% gets attention given MAESTRO-NASH delivered 26-30%; above 40% would be class-leading among injectables and force a Phase 3 commitment; matching ESSENCE's 62.9% [10] would be a step-change. Secondary signal: the compensated cirrhosis arm. Positive safety and efficacy in F4 patients would give Merck a clean wedge versus resmetirom, which excluded that population [3]. Check back at Merck's Q4 2026 earnings call or AASLD The Liver Meeting (typically November) for the precirrhotic NASH readout. If the data is mediocre, expect Merck to quietly de-prioritize and let survodutide or pemvidutide carry the dual-agonist banner. If it's strong, expect a Phase 3 announcement within two quarters of the readout.